Goeckerman regimen: Genotoxic, pro-apoptotic, anti-inflammatory and anti-angiogenic effect

Dermatology Research Focus on Acne, Melanoma and Psoriasis

Volumn , Issue , 2010, Pages 141-163

  Borska, L ^a   Fiala, Z ^a   Andrys, C ^b   Krejsek, J ^c   Hamakova, K ^c  

^a Department of Clinical Immunology and Allergology ^*  (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900310325     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (141)

1. Acta Hygienica et Epidemiologica et Microbiologica (AHEM). Standardized operating approaches for biological monitoring of genotoxic effects of environmental factors. AHEM 3/2003. National Institute of Health, Praha, 2003.
2. Andrys, C; Borska, L; Pohl, D; Fiala, Z; Hamakova, K; Ettler, K; Krejsek, J. Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level. Int J Dermatol, 2008, 47(10), 1011-1014.
3. Andrys, C; Borska, L; Pohl, D; Fiala, Z; Hamakova, K; Krejsek, J. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy. Arch Dermatol Res, 2007, 298(10), 479-483.
4. Andrys, C; Pozler, O; Krejsek, J; Derner, V; Drahosova, M; Kopecky, O. Serum soluble adhesion molecules (sICAM-1, sVCAM-1 and sE-selectin) in healthy school aged children and adults. Acta Med (Hradec Kralove), 2000, 43(3), 103-106.
5. Arbiser, JL; Govindarajan, B; Battle, TE; Lunch, R; Frank, DA; Usnio-Fukai, M; Perry, BN; Stern, DF; Bowden, GT; Liu, A; Klein, E; Kolodziejski, PJ; Eissa, NT; Hossain, ChF; Nagle, DG. Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol, 2006, 126(6), 1396-1402.
6. Arfsten, DP; Schaeffer, DJ; Mulveny, DC. The effects of near ultraviolet radiation on the toxic effects of polycyclic aromatic hydrocarbons in animals and plants: a review. Ecotoxicol Environ Saf, 1996, 33(1), 1-24.
7. Arican, O; Aral, M; Sasmaz, S; Ciraqil, P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm, 2005, 2005(5), 273-279.
8. Arnold, WP. Tar. Clin Dermatol, 1997, 15(5), 739-744.
9. Arrigo, AP. [Heat shock proteins as molecular chaperones]. Med Sci (Paris), 2005, 21(6-7), 619-625.
10. Aufricht, C. HSP: helper, suppressor, protector. Kidney Int, 2004, 65(2), 739-740.
11. Azfar, RS; Gelfand, JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rhematol, 2008, 20(4), 416-422.
12. Bevelacqua, V; Libra, M; Mazzarino, MC; Gangemi, P; Nicotra, G; Curatolo, S; Massimino, D; Plumari, A; Merito, P; Valent, G; Stivala, F; La Greca, S; Malaponte, G. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med, 2006, 18(3), 415-423.
13. Bhushan, M; McLaughlin, B; Weiss, JB; Griffiths, CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol, 1999, 141(6), 1054-1060.
14. Boffetta, P; Gridley, G; Lindelöf, B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol, 2001, 117(6), 1531-1537.
15. Boffetta, P; van der Hel, O; Norppa, H; Fabianova, E; Fucic, A; Gundy, S; Lazutka, J; Cebulska-Wasilewska, A; Puskailerova, D; Znaor, A; Kelecsenyi, Z; Kurtinaitis, J; Rachtan, J; Forni, A; Vermeulen, R; Bonassi, S. Chromosomal aberrations and cancer risk: results of a cohort study from Central Europe. Am J Epidemiol, 2007, 165(1), 36-43.
16. Borska, L; Andrys, C; Krejsek, J; Hamakova, K; Kremlacek, J; Ettler, K; Fiala, Z. Serum levels of pro-inflammatory cytokine IL-12 and anti-inflammatory cytokine IL-10 in patients with psoriasis treated by Goeckerman Regimen. Int J Dermatol, 2008, 47(8), 800-805.
17. Borska, L; Andrys, C; Krejsek, J; Hamakova, K; Kremlacek, J; Ettler, K; Vellappally, S; Vimal, J; Fiala, Z. Genotoxic hazard and cellular stress in pediatric patients treated for psoriasis with the Goeckerman Regimen. Pediatr Dermatol, 2009, 26(1), 23-27a.
18. Borska, L; Andrys, C; Krejsek, J; Hamakova, K; Kremlacek, J; Ranna, D; Kotingova, L; Fiala, Z. Plasma levels of p53 protein and chromosomal abberations in patients with psoriasis treated by Goeckerman Regimen. Clin Exp Dermatol, 2009b. [Epub ahead of print]
19. Borska, L; Andrys, C; Krejsek, J; Hamakova, K; Kremlacek, J; Ranna, D; Kotingova, L; Fiala, Z. Genotoxic and apoptotic fffects of Goeckerman therapy for psoriasis. Int J Dermatol, 2009c. [Epub ahead of print]
20. Borska, L; Fiala, Z; Krejsek, J; Andrys, C; Vokurkova, D; Hamakova, K; Kremlacek, J; Ettler, K. Selected immunological changes in patients with Goeckerman's therapy TNF-alpha, sE-selectin, sP-selectin, sICAM-1 and IL-8. Physiol Res, 2006, 55(6), 699-706a.
21. Borska, L; Fiala, Z; Krejsek, J; Andrys, C; Vokurkova, D; Hamakova, K; Kremlacek, J; Ettler, K. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol, 2007, 24(6), 607-612.
22. Borska, L; Fiala, Z; Krejsek, J; Hamakova, K; Andrys, C; Smejkalova, J; Vokurkova, D; Kremlacek, J. Cytogenetic and immunological changes after dermal exposure to polycyclic aromatic hydrocarbons and UV radiation. Physiol Res, 2006, 55(3), 317-323b.
23. Borska, L; Fiala, Z; Smejkalova, J; Hamakova, K; Kremlacek, J. Possible genotoxic risk of combined exposure to pharmaceutical coal tar and UV-B radiation. Cent Eur J Publ Health, 2004, 12(Suppl), 14-15.
24. Bos, JD; Spuls, PI. Topical treatments in psoriasis: today and tomorrow. Clin Dermatol, 2008, 26(5), 432-437.
25. Bos, WE; Thio, HB; Neumann, HA; van der Fits, L; Prens EP. The pathogenesis of inflammatory dermatoses, especially psoriasis. Ned Tijdschr Geneeskd, 2006, 28, 150(4), 179-183. [Article in Dutch]
26. Bouïs, D; Kusumanto, Y; Meijer, C; Mulder, NH; Hospers, GA. A review on pro-and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res, 2006, 53(2), 89-103.
27. Bowman, DL; Smith, CJ; Bombick, BR; Avalos, JT; Davis, RA; Morgan, WT; Doolittle, DJ. Relationship between FTC tarand urine mutagenicity in smokers of tobacco-burning or Eclipse cigarettes. Mutat Res, 2002, 521(1-2), 137-149.
28. Brandt-Rauf, PW; Pincus, MR. Molecular markers of carcinogenesis. Pharmacol Ther 1998, 77(2), 135-148.
29. Brendler-Schwaab, S; Czich, A; Epe, B; Gocke, E; Kaina, B; Müller, L; Pollet, D. Utesch, D. Photochemical genotoxicity: principles and test methods. Report of a GUM task force. Mutat Res, 2004, 566(1), 65-91.
30. Burchiel, SW; Luster, MI. Signaling by environmental polycyclic aromatic hydrocarbons in human lymphocytes. Clin Immunol, 2001 98(1), 2-10.
31. Castranova, V; Ma, JY; Yang, HM; Antonini, JM; Butterworth, L; Barger, MW; Roberts, J; Ma, JK. Effect of exposure to diesel exhaust particles on the susceptibility of the lung to infection. Environ Health Perspect, 2001, 109(4), 609-612.
32. Cerna, M; Pastorkova, A. Bacterial urinary mutagenicity test for monitoring of exposure to genotoxic compounds: a review. Cent Eur J Public Health, 2002, 10(3), 124-129.
33. Christophers, E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol, 2001, 26(4), 314-320.
34. Clonfero, E; Jongeneelen, F; Zordam, M; Levis, AG. Biological monitoring of human exposure to coal tar. Urinary mutagenicity assays and analytical determination of polycyclic aromatic hydrocarbon metabolites in urine. IARC Sci Publ, 1990, (104), 215-222.
35. Cosmetic Ingredient Review Expert Panel. Final safety assessment of coal tar as used in cosmetics. Int J Toxicol, 2008, 27(Suppl2), 1-24.
36. Cruz-Rodriguez, LA; Chu, FL. Heat-shock protein (HSP70) response in the eastern oyster, Crassostrea virginica, exposed to PAHs sorbed to suspended artificial clay particles and to suspended field contaminated sediments. Aquat Toxicol, 2002, 60(3-4),157-168.
37. Danielsen, AG; Heidenheim, M; Wulf, HC. Crude coal tar treatment every day versus every other day for plaque psoriasis. Acta Derm Venereol, 2001, 81(3), 221-222.
38. de Rie, MA; Goedkoop, AY; Bos, JD. Overview of psoriasis. Dermatol Ther, 2004, 17(5), 341-349.
39. Druzhinin, VG; Minina, VI; Mokrushina, NV. [Cytogenetic disorders in workers of coal-tar chemical industry]. Med Tr Prom Ekol, 2000, (10), 22-24.
40. Environmental Protection Agency (EPA). Toxicological Profile for Polycyclic Hydrocarbons (PAHs). Washington, DC: Environmental Protection Agency, 1994.
41. Feldman, SR. Where has Goeckerman treatment gone? J Dermatolog Treat, 2005, 16(2), 73-74.
42. Fiala, Z; Borska, L; Pastorkova, A; Kremlacek, J; Cerna, M; Smejkalova, J; Hamakova, K. Genotoxic effect of Goeckerman regimen of psoriasis. Arch Dermatol Res, 2006, 298(5), 243-251.
43. Folkman, J. Angiogenesis. Annu Rev Med, 2006, 57, 1-18.
44. Food and Drug Administration, HHS (FDA). Dandruff, seborrheic dermatitis, and psoriasis drug products containing coal tar and menthol for over-the counter human use; amendment to the monograph. Final rule. Fed Regist, 2007, 72(43), 9849-9852.
45. Gardosova, D; Mezencevova, V; Kalina, I; Hejj, F; Kopka, M; Petrovicova, J. [Mutagenic effects of coal tar used in the treatment of psoriasis]. Bratisl Lek Listy, 1997, 98(3), 146-149.
46. Gaspari, MD. Innate and adaptive immunity and the pathophysiology of psoriasis. J M Acad Dermatol, 2006, 54(3), 67-80.
47. Gelfand, JM; Shin, DB; Neimann, AL; Wang, X; Margolis, DJ; Troxel, AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol, 2006, 126(10), 2194-2201.
48. Gmeier, G; Krassnig, C; Schmidt, E; Tausch, H. Fast screening method for the profile analysis of polycyclic aromatic hydrocarbon metabolites in urine using derivatization-solid-phase micro extraction. J Chromatogr B, 1998, 705, 132-138.
49. Goeckerman, WH. Treatment of psoriasis. Continued observations on the use of crude coal tar and ultraviolet light. Archives Dermatol, 1925, 24, 446-450.
50. Golda, N; Benham, SM; Koo, J. Reboud of psoriasis during treatment with efalizumab. J Drugs Dematol, 2006, 5(1), 63-65.
51. Gottlieb, AB; Leonardi, CL; Goffe, BS; Ortonne, JP; van der Kerkhof, PC; Zitnik, R; Nakanishi, A; Jahreis, A. Etanercept monotherapy in patients with psoriasis: a summary of safety based on an integrated multistudy database. J Am Acad Dermatol, 2006, 54(Suppl 2), 92-100.
52. Goulaouic, S; Foucaud, L; Bennasroune, A; Laval-Gilly, P; Falla, J. Effect of polycyclic aromatic hydrocarbons and carbon black particles on pro-inflammatory cytokine secretion: impact of PAH coating onto particles. J Immunotoxicol, 2008, 5(3), 337-345.
53. Green, DR. Apoptotic pathway: the roads to ruin. Cell, 1998, 94(6), 695-698.
54. Griffiths, CE; Barker, JN. Pathogenesis and clinical features of psoriasis. Lancet, 2007, 370(9583), 263-271.
55. Hainaut, P; Hernandez, T; Robinson, A; Rodriguez-Tome, P; Flores, T; Hollstein, M; Harris, CC; Montesano, R. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and visualization tools. Nucleic Acids Res, 1998, 26(1), 205-213.
56. Hannuksela-Svahn, A; Pukala, E; Läärä, E; Poikolainen, K; Karvonen, J. Psoriasis, its treatment, and cancer in a cohort of Finish patients. J Invest Dermatol, 2000, 114(3), 587-590.
57. Hansen, AM; Mathiesen, L; Pedersen, M; Knudsen, LE. Urinary 1-hydroxypyrene (1-OHP) in environmental and occupational studies-a review. Int J Hyg Environ Health, 2008, 211(5-6), 471-503.
58. Hecht, SS; Chen, M; Yagi, H; Jerina, DM; Carmella, SG. r-1, t-2,3, c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthere in human urine: a potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation. Cancer Epidemiol Biomarkers Prev, 2003, 12(12), 1501-1508.
59. Heidenreich, R; Röcken M; Ghoreschi, K. Angiogenesis: the new potential target for the therapy of psoriasis? Drug News Perspect, 2008, 21(2), 97-105.
60. Huang, W; Smith, TJ; Ngo, L; Wang, T; Chen, H; Wu, F; Herrick, RF; Christiani, DC; Ding, H. Characterizing and biological monitoring of polycyclic aromatic hydrocarbons in exposures to diesel exhaust. Environ Sci Technol, 2007, 41(8), 2711-2716.
61. International Agency for Research on Cancer (IARC). Monographs on the Evaluation Carcinogenic Risk of Chemicals to Humans. Vols. 1-42. Overal Evaluations of Carcinogenicity. An updating IARC Monographs. IARC, Lyon (Suppl 7), 1987.
62. International Agency for Research on Cancer (IARC). Monographs on the Evaluation of Carcinogenic Risks to Humans. Solar and Ultraviolet Radiation. An updating IARC Monograph. IARC, Lyon (Suppl 55), 1992.
63. Jacob, SE; Nassiri, M; Kerdel, FA; Vincek, V. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators of Inflammation, 2003, 12(5), 309-313.
64. Jones, CD; Guckian, M; el-Ghorr, AA; Gibbs, NK; Norval, M. Effects of phototherapy on the production of cytokines by peripheral blood mononuclear cells and on systemic antibody responses in patients with psoriasis. Photodermatol Photoimmunol Photomed, 1996, 12(5), 204-210.
65. Katiyar, SK. Interleukin-12 and photocarcinogenesis. Toxicol Appl Pharmacol, 2007, 224(3), 220-227.
66. Kim, E; Kang, BY; Kim, TS. Inhibition of interleukin-12 production in mouse macrophages by hydroquinone, a reactive metabolite of benzene, via suppression of nuclear factor-kappaB binding activity. Immunol Lett, 2005, 99(1), 24-29a.
67. Kim, SR; Kokubo, K; Matsui, K; Yamada, N; Kanke, Y; Fukuoka, M; Yamada, M; Nohmi, T. Light-dependent mutagenesis by benzo[a]pyrene is mediated via oxidative DNA damage. Environ Mol Mutagen, 2005, 46(3), 141-149b.
68. Kolomecki, K; Maciaszczyk, P; Stepien, H; Stepien, T; Kuzdak, K; Ulanska, J. p53 concentration and soluble FasL (sFasL) serum level as indicators of apoptosis in patients with benign and malignant thyroid tumors. Bratisl Lek Listy, 2005 106(10), 297-300.
69. Kormeili, T; Lowe, NJ; Yamauchi, PS. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br J Dermatol, 2005, 152(4), 817-818.
70. Kozlowski, M; Kowalczuk, O; Sulewska, A; Dziegielewski, P; Lapuc, G; Laudanski, W; Niklinska, W; Chyczewski, L; Niklinski, J; Laudanski, J. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus. Folia Histochem Cytobiol, 2007, 45(3), 199-204.
71. Krajewska, B; Lutz, W; Pilacik, B. Determination of blood serum oncoprotein NEU and antioncoprotein p-53-molecular biomarkers in various types of occupational exposure. Int J Occup Med Environ Health, 1998, 11(4), 343-348.
72. Kregel, KC. Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J Appl Physiol, 2002, 92(5), 2177-2186.
73. Kuljukka-Rabb, T; Nylund, L; Vaaranrinta, R; Savela, K; Mutanen, P; Veidebaum, T; Sorsa, M; Rannug, A; Peltonen, K. The effect of relevant genotypes on PAH exposure-related biomarkers. J Expo Anal Environ Epidemiol, 2002, 12(1), 81-91.
74. Lai, CS; Juany, PH; Ho, JC. Treatment for psoriasis with modified Goeckerman regiment One year experience in southern Taiwan. Dermatologica Sinica, 2005, 13(3), 113-120.
75. Lalic, H; Radosevic-Stasic, B. Chromosome aberrations in peripheral blood lymphocytes in subjects occupationally exposed to ionizing radiation or chemical clastogens. Folia Biol (Praha), 2002, 48(3), 102-107.
76. Laupeze, B; Amiot, L; Sparfel, L; Le Ferrec, E; Fauchet, R; Fardel, O. Polycyclic aromatic hydrocarbons affect functional differentiation and maturation of human monocyte-derived dendritic cells. J Imunology, 2002, 168(6), 2652-2658.
77. Leculeur, V; Ferrec, EL; N'diaye, M; Vee, ML; Gardyn, C; Gilot, D; Fardel, O. ERK-dependent induction of TNF-alpha expression by the environmental contaminant benzo(a)pyrene in primary human macrophages. FEBS Lett, 2005, 579(9), 1904-1910.
78. Lee, E; Koo, J. Modern modified 'ultra' Goeckerman therapy: A PASI assessment of a very effective therapy for psoriasis resisment to both prebiologic and biologic therapies. J Dermatological Treat, 2005, 16(2), 102-107.
79. Legret, M; Odie, L; Demare, D; Jullien, A. Leaching of heavy metals and polycyclic aromatic hydrocarbons from reclaimed asphalt pavement. Water Res, 2005, 39(15), 3675-3685.
80. Leon, A; Nquyen, A; Letsinger, J; Koo, J. An attempt to formulate an evidence-based strategy in the management of moderate-to severe psoriasis: a review of the efficiency and safety of biologics and prebiologic options. Expert Opin Pharmacother, 2007, 8(5), 617-632.
81. Leong, TT; Fearon, U; Veale, DJ. Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheumatol Rep, 2005, 7(4), 325-329.
82. Lim, HW; Anderson, TF; Douglass, M; Koo, J; Lebwohl, M; Morison, W; Taylor, C; Zanolli, M. Cost-effectiveness of methotrexate and Goeckerman Therapy: a flawed analysis. Arch Dermatol, 1999, 135(6), 717-718.
83. Lowes, MA; Bowcock, AM; Krueger, JG. Pathogenesis and therapy of psoriasis. Nature, 2007, 445(7130), 866-873.
84. Ma, JY; Rengasamy, A; Frazer, D; Barger, MW; Hubbs, AF; Battelli, L; Tomblyn, S; Stone, S; Castranova, V. Inhalation exposure of rats to asphalt fumes generated at paving temperatures alters pulmonary xenobiotic metabolism pathway without lung injury. Environ Health Perspect, 2003, 111(9), 1215-1221.
85. Mahadevan, B; Marston, CP; Dashwood, WM; Li, Y; Pereire, C; Baird, WM. Effect of a standardized complex mixture derived from coal tar on the metabolic activation of carcinogenic polycyclic aromatic hydrocarbons in human cells in culture. Chem Res Toxicol, 2005, 18(2), 224-231.
86. Major, J; Jakab, MG; Tompa, A. Working condition-related improvement in genotoxicological parameters of Hungarian road pavers. J Toxicol Environ Health, 2001, 62(5), 319-331.
87. Mantovani, A; Garlanda, C; Doni, A; Bottazzi, B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol, 2008, 28(1), 1-13.
88. Marvanova, S; Vondracek, J; Pencikova, K; Trilecova, L; Krcmarr, P; Topinka, J; Novakova, Z; Milcova, A; Machala, M. Toxic effect of methylated benz(a)antracenes in liver cells. Chem Res Toxicol, 2008, 21(2), 503-512.
89. Massari LP, Kastelan M, Gruber F. Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis. Coll Antropol, 2007, 31(Suppl 1), 83-85.
90. Menter, A; Grifiths, ChEM: Current and future management of psoriasis. Psoriasis 2. Lancet, 2007, 370(9583), 272-284.
91. Merwald, H; Kokesch, C; Klosner, G; Matsui, M; Trautinger, F. Induction of the 72-kilodalton head shock protein and protection from ultraviolet B-induced cell death in human keratinocytes by repetitive exposure to heat shock or 15-deoxy-delta(12,14)-prostaglandin J2. Cell Stress Chaperones, 2006, 11(1), 81-88.
92. Molho-Pessach, V; Lotem, M. Ultraviolet radiation and cutaneous carcinogenesis. Curr Probl Dermatol, 2007, 35, 14-27.
93. Mukhtar, H; DelTito, BJJr; Matgouranis, PM; Das, M; Asokan, P; Bickers, DR. Additive effects of ultraviolet B and trude coal tar on cutaneous karcinogen metabolism: possible relevance to the tumorigenicity of the Goeckerman regiment. J Invest Dermatol, 1986, 87(3), 348-353.
94. N'diaye, M; Le Ferrec, E; Lagadic-Gossmann, D; Corre, S; Gilot, D; Lecureur, V; Monteiro, P; Rauch, C; Galibert, MD; Fardel, O. Aryl hydrocarbon receptor- and calcium dependent induction of the chemokine CCL1 by the environmental contaminant benzo(a)pyrene. J Biol Chem, 2006, 281(29), 19906-19915.
95. Naldi, L; Griffiths, CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol, 2005, 152(4), 597-615.
96. Nickoloff, BJ; Qin, JZ; Nestle, FO. Immunopathogenesis of Psoriasis. Clinic Rev Allerg Immunol, 2007, 33(1-2), 45-56.
97. Numerof, RP; Asadullah, K. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs, 2006, 20(2), 93-103.
98. Pacheco, KA; Tarkowski, M; Sterritt, C; Negri, J; Rosenwasser, LJ; Borish, L. The influence of diesel exhaust particles on mononuclear phagocytic cell-derived cytokines: IL-10, TGF-beta and IL-1 beta. Clin Exp Immunol, 2001, 126(3), 374-383.
99. Page, TJ; Óbrien, S; Jefcoate, CR; Czuprynski, CJ. 7,12-Dimethylbenz(a)antracene induces apoptosis in murine pre B-cells through a caspase 8-dependent pathway. Mol Pharmacol, 2002, 62(2), 313-319.
100. Paghdal, KV; Schwartz, RA. Topical tar: Back to the future. J Am Acad Dermatol, 2009 [Epub ahead of print]
101. Pan, G; Hanaoka, T; Yamano, Y; Hara, K; Ichiba, M; Wang, Y; Zhang, J; Feng, Y; Shujuan, Z; Guan, D; Gao, G; Liu, N; Takahashi, K. A study of multiple biomarkers in coke oven workers-a cross-sectional study in China. Carcinogenesis, 1998, 19(11), 1963-1968.
102. Pandya, NM; Dhalla, NS; Santani, DD. Angiogenesis-a new target for future therapy. Vascul Pharmacol, 2006, 44(5), 265-274.
103. Pastorkova, A; Cerna, M; Smid, J; Vrbikova, V. Mutagenicity of airborne particulate matter PM10. Cent Eur J Public Health, 2004, 12 (Suppl), S72-75.
104. Pearce, DJ; Stealey, KH; Balkrishnan, R; Fleischer, AB; Feldman, SR. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol, 2006, 45(4), 370-374.
105. Pion, IA; Kleniq, KL; Lim, HW. Is dermatologic usage of coal tar carcinogenic? A reviewed of the literature. Dematol Surg, 1995, 21(3), 227-231.
106. Prinz, JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol, 2003, 17(3), 257-270.
107. Prodanowich, S; Kirsner, RS; Tailor, JR. Treatment of patients hospitalized for psoriasis. Dermatol Clin, 2000, 18(3), 425-435.
108. Rass, K; Reichrath, J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv Exp Med Biol, 2008, 624, 162-178.
109. Roelofzen, JH; Aben, K; Oldenhof, U; Coenraads, PJ; Alkemade, H; van de Kerkhof, PC; van der Valk, PG; Kiemeney, L. Abstract A114: No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. Cancer Prev Res, 2008, 1(7Suppl), A114.
110. Roelofzen, JH; Aben, KK; Khawar, AJ; van de Kerkhof, PC; Kiemeney, LA; van der Valk, PG. Treatment policy for psoriasis and eczema: a survey among dermatologists in the Netherlands and Belgian Flanders. Eur J Dermatol, 2007, 17(5), 416-421b.
111. Roelofzen, JH; Aben, KK; van der Valk, PG; van Houtum, JL; van de Kerkhof, PC; Kiemeney, LA. Coal tar in dermatology. J Dermatolog Treat, 2007, 18(6), 329-334a.
112. Rössner, P; Boffeta, P; Ceppi, M; Bonassi, S; Smerhovsky, Z; Landa, K; Juzova, D; Srám, RJ. Chromosomal aberations in lymphocytes of healthy subjects and risk of cancer. Environ Health Perspect, 2005, 113(5), 517-520.
113. Rössner, P Jr; Binkova, B; Milcova, A; Solansky, I; Zidzik, J; Lyubomirova, KD; Farmer, PB; Sram, RJ. Air pollution by carcinogenic PAHs and plasma levels of p53 and p21 (WAF1) proteins. Mutat Res, 2007, 620(1-2), 34-40.
114. Roussaki-Schulze, AV; Kouskoukis, C; Petinaki, E; Klimi, E; Zafiriou, E; Galanos, A; Rallis, E. Evaluation of cytokine serum levels in patients with plaque-type psoriasis. Int J Clin Pharmacol Res, 2005, 25(4), 169-173.
115. Sabat, R; Philipp, S; Höflich, C; Kreutzer, S; Wallace, E; Asadullah, K; Volk, HD; Sterry, W; Wolk, K. Immunopathogenesis of psoriasis. Experimental Dermatol, 2007, 16(10), 779-798.
116. Schwarz, A; Schwarz, T. Molecular determinats of UV-induced immunosupression. Exp Dermatol, 2002, 11(Suppl1), 9-12.
117. Serdar, B; Waidyanatha, S; Zheng, Y; Rappaport, SM. Simultaneous determination of urinary 1- and 2-naphthols, 3- and 9- phenanthrols, and 1-pyrenol in coke oven workers. Biomarkers, 2003, 8(2), 93-109.
118. Serrao, R; Davis, MD. Goeckerman treatment for remission of psoriasis refractory to biologic therapy. J Am Acad Dermatol, 2009, 60(2), 348-349.
119. Siwinska, E; Mielzyńska, D; Kapka, L. Association between urinary 1-hydroxypyrene and genetoxic effects in coke oven workers. Occup Environ Med, 2004, 61(3), e10.
120. Soares, TF; Davis, MD. Success of Goeckerman treatment in 2 patients with psoriasis not responding to biological drugs. Arch Dermatol, 2007, 143(7), 950-951.
121. Sorsa, M; Wilbourn, J; Vainio, H. Human cytogenetic damage as a predictor of cancer risk. IARC Sci Publ, 1992, (116), 543-554.
122. Soti, C; Csarmely, P. Aging and molecular chaperones. Exp Gerontol, 2003, 38(10), 1037-1040.
123. Soti, C; Nagy, E; Giricz, Z; Vígh, L; Csermely, P; Ferdinandy, P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol, 2005, 146(6), 769-780.
124. Sram, RJ; Beskid, O; Binkova, B; Chvatalova, I; Lnenickova, Z; Milcova, A; Solansky, I; Tulupova, E; Bavorova, H; Ocadlikova, D; Farmer, PB. Chromosomal aberrations in environmentally exposed population in relation to metabolic and DNA repair genes polymorphisms. Mutat Res, 2007, 620(1-2), 22-33.
125. Stern, RS; Scotto, J; Fears, TR. Psoriasis and susceptibility to nonmelanoma skin cancer. J Am Acad Dermatol, 1985, 12(1Pt1), 67-73.
126. Sylvester, B. Goeckerman method effective and safe for childrenpsoriasis, Mayo Researchers Report: Presented at AAD, 2007. URL:http://www.docguide.com/news/content.nsf/news/852571020057CCF68525727A006550F5
127. Szegedi, A; Aleksza, M; Gonda, A; Irinyi, B; Sipka, S; Hunyadi, J; Antal-Szalmas, P. Elevated rate of Thelper1 (Th1) lymphocytes and serum IFN-y levels in psoriatic patients. Immunology Letters, 2003, 86(3), 277-280.
128. Thami, GP; Sarkar, R. Coal tar: past, present and future. Clin Exp Dermatol, 2002, 27(2), 99-103.
129. Topinka, J; Marvanova, S; Vanderval, J; Sevastyanova, O; Novakova, Z; Krcmar, P; Pencikova, K; Machala, M. DNA adducts formation and induction of apoptosis in rat liver epitelial "stem-like" cells exposed to carcinogenic polycyclic aromatic hydrocarbons. Mutat Res, 2008, 638(1-2), 122-132.
130. Trautinger, F. Heat shock proteins in the photobiology of human skin. J Photochem Photobiol B, 2001, 63(1-3), 70-77.
131. Tremblay, JF; Bissonnette, R. Topical agents for the treatment of psoriasis, past, present and future. J Cutan Med Surg, 2002, 6(3), 8-11.
132. van de Kerkhof, PC; Barker, J; Griffiths, CE; Kragballe, K; Mason, J; Menter, A; Papp, K. Psoriasis: consensus on topical therapies. J Eur Acad Dermatol Venereol, 2008, 22(7), 859-870.
133. Veenhuis, RT; van Horssen, J; Bos, RP; Anzion, RB; van der Valk, PG. Highly increased urinary 1-hydroxypyrene excretion rate in patients with atopic dermatitis treated with topical coal tar. Arch Dermatol Res, 2002, 294(4), 168-171.
134. Veraldi, A; Costantini, AS; Bolejack, V; Miligi, L; Vineis, P; van Loveren H. Immunotoxic effects of chemicals: A matrix for occupational and environmental epidemiological studies. Am J Ind Med, 2006, 49(12), 1046-1055.
135. Vousden, KH; Lane, DP. p53 in health and disease. Nat Rev Mol Cell Biol, 2007, 8(4), 275-283.
136. Walters, IB; Ozawa, M; Cardinale, I; Gilleaudeau, P; Trepicchio, WL; Bliss, J; Krueger, JG. Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: differential regulation of cytokines at the single-cell level. Arch Dermatol, 2003, 139(2), 155-161.
137. Weber, LP. Acute ex vivo effects of dimethylbenz[a]anthracene and heat shock on rat tail artery. Cardiovasc Toxicol, 2004, 4(4), 355-362.
138. Yano, K; Kadoya, K; Kajiya, K; Hong, YK; Detmar, M. Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol, 2005, 152(1), 115-121.
139. Yoshizumi, M; Nakamura, T; Kato, M; Ishioka, T; Kozawa, K; Wakamatsu, K; Kimura, H. Release of cytokines/chemokines and cell death in UVB-irradiated human keratinocytes, HaCaT. Cell Biol Int, 2008, 32(11), 1405-1411.
140. Zampetti, A; Barone, A; Antuzzi, D; Amerio, P; Tulli, A; Feliciani, C; Amerio, P. Topical preparations for the treatment of psoriasis: results of a retrospective study over 15 years. J Dermatolog Treat, 2008, 19(3), 134-140.
141. Zhou, T; Mountz, JD; Kimberly, RP. Immunobiology of tumor necrosis factor receptor superfamily. Immunol Res, 2002, 26(1-3), 323-336.